Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Drug

Evopoint Biosciences Enrolls First Patient in Phase III Trial for Gout Drug XNW3009

Fineline Cube Feb 8, 2024

Suzhou-based Evopoint Biosciences Co., Ltd. has announced the enrollment of its first patient in a...

Company Drug

ChinaGene Secures CDE Approval for ZVS101e Gene Therapy Targeting Retinitis Pigmentosa

Fineline Cube Feb 8, 2024

Beijing-based ChinaGene Technology Co., Ltd. has announced that it has received tacit clinical approval from...

Company Deals

Yantai Dongcheng Acquires Full Rights to Alfatide II, Targeting Diagnostic and Therapeutic Applications

Fineline Cube Feb 8, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has announced its acquisition of all rights...

Company Drug

Nanjing Zenshine’s ZX-7101A NDA Accepted by NMPA for Uncomplicated Influenza Treatment

Fineline Cube Feb 8, 2024

Nanjing Zenshine Pharmaceuticals Co., Ltd., a China-based small molecule drug developer, has announced that the...

Company

Gilead’s 2023 Flat Sales Reflect Stagnation and COVID-19 Demand Decline

Fineline Cube Feb 7, 2024

Gilead Sciences Inc. (NASDAQ: GILD) has reported a stagnant performance for the year 2023, with...

Company

Astellas Pharma Inc. Reports 2.1% YOY Growth in Q1-Q3 Fiscal 2023 Revenues

Fineline Cube Feb 7, 2024

Tokyo-based pharmaceutical company Astellas Pharma Inc., (TYO: 4503) has announced financial results for the first...

Company

Gilead’s 2023 Stagnation Foresees Flat 2024 Sales as Veklury Revenues Dwindle

Fineline Cube Feb 7, 2024

Gilead Sciences (NASDAQ: GILD) has reported a stagnant performance for 2023, with product sales remaining...

Company

Amgen’s Q4 2023 Results Showcase 9% YOY Growth, 18 Drugs Hit Record Sales

Fineline Cube Feb 7, 2024

Biopharmaceutical giant Amgen (NASDAQ: AMGN) has reported its financial results for Q4 2023, announcing annual...

Policy / Regulatory

Medical Institutions Directed to Adhere to ‘Six Should Do’s’ and ‘Six Prohibited Behaviors’ for Academic Lectures

Fineline Cube Feb 7, 2024

Medical institutions have reportedly been circulated with a “Notice on Issuing Work Tips for Medical...

Policy / Regulatory

China Proposes Market-Oriented Pricing for Innovative Drugs to Boost High-Quality Development

Fineline Cube Feb 7, 2024

The National Healthcare Security Administration (NHSA) has unveiled a draft Notification on “Establishing a Price...

Company

Eli Lilly’s 2023 Revenue Soars on Metabolism Drugs, Anticipates Further Growth in 2024

Fineline Cube Feb 7, 2024

Eli Lilly and Company (NYSE: LLY) reported a robust 2023 financial performance with a 20%...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for Phase II Study of GLP-1 Agonist for Weight Loss

Fineline Cube Feb 7, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company

Innovent Biologics Posts 65% YOY Growth in Q4 2023 with Over RMB 1.6 Billion in Sales

Fineline Cube Feb 7, 2024

Chinese biopharmaceutical company Innovent Biologics Inc., (HKG: 1801) has reported impressive quarterly sales figures, announcing...

Company Drug

Shanghai Procurement Platform Offers Price Cut Leeway to Escape ‘High-Priced Drugs’ Tag

Fineline Cube Feb 7, 2024

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) platform has announced a significant policy shift regarding non-winning...

Company Drug

BioNTech and Duality’s DB-1305 Earns Fast-Track Status for Platinum-Resistant Cancers

Fineline Cube Feb 7, 2024

German biotechnology company BioNTech SE (NASDAQ: BNTC) and its partner Duality Biologics (Suzhou) Co., Ltd...

Policy / Regulatory

NMPA Reports Record 61 Innovative Medical Device Approvals in 2023

Fineline Cube Feb 6, 2024

The National Medical Products Administration (NMPA) has released its 2023 medical device filings work report,...

Company Deals

Novartis to Acquire MorphoSys for €2.7 Billion in Strategic Oncology Expansion

Fineline Cube Feb 6, 2024

Switzerland-based Novartis (NYSE: NVS) has announced a voluntary public takeover offer to acquire Germany-based biopharmaceutical...

Company Deals

Bayer Partners with TetraScience to Enhance Data Management in Product Development

Fineline Cube Feb 6, 2024

Germany-based Bayer (ETR: BAYN) has announced a partnership with data management firm TetraScience to collect...

Company Deals

Zhejiang Anglikang Enters R&D Cooperation Agreement with Affinity Biopharmaceutical

Fineline Cube Feb 6, 2024

China-based Zhejiang Anglikang Pharmaceutical Co., Ltd. (SHE: 002940) has entered into a research and development...

Company Deals

Novo Holdings to Acquire Catalent for $16.5 Billion in Strategic Move to Enhance Biopharmaceutical Capacity

Fineline Cube Feb 6, 2024

Novo Holdings, the principal shareholder of Denmark’s Novo Nordisk (CPH: NOVO-B), has announced a definitive...

Posts pagination

1 … 394 395 396 … 658

Recent updates

  • Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
  • Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms
  • Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design
  • BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C
  • Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Others

Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms

Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.